Title |
The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction
|
---|---|
Published in |
Research and Reports in Urology, April 2013
|
DOI | 10.2147/rru.s31580 |
Pubmed ID | |
Authors |
Mauro Gacci, Matteo Salvi, Arcangelo Sebastianelli, Linda Vignozzi, Giovanni Corona, Kevin T McVary, Steven A Kaplan, Mario Maggi, Marco Carini, Matthias Oelke |
Abstract |
A strong and independent association between lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and erectile dysfunction (ED) has been widely evidenced in several clinical epidemiologic studies. Preclinical animal models have provided a great deal of information on potential common pathogenic mechanisms underlying these two clinical identities. Although the efficacy of the most commonly used treatments for LUTS/BPH is well defined, the negative impact of these treatments on sexual function - in particular, on ED - has triggered the search for new treatment options. In this regard, a new role for phosphodiesterase type 5 inhibitors in the treatment of LUTS/BPH and ED has been claimed. Tadalafil is one of the most extensively investigated phosphodiesterase type 5 inhibitors for this new indication. All evidence reported to date suggests that tadalafil 5 mg once daily is a safe and effective treatment option for both LUTS/BPH and ED. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 36 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 17% |
Student > Ph. D. Student | 5 | 14% |
Other | 4 | 11% |
Student > Doctoral Student | 2 | 6% |
Student > Bachelor | 2 | 6% |
Other | 5 | 14% |
Unknown | 12 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 31% |
Computer Science | 3 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Psychology | 1 | 3% |
Other | 3 | 8% |
Unknown | 15 | 42% |